Dr Jon Gil-Ranedo
Profiles

Dr Jon Gil-Ranedo

Research Fellow in Cancer Stem Cell Neurobiology

Peninsula Medical School (Faculty of Health)

Research Fellow in Cancer Stem Cell Neurobiology, Peninsula Medical School, Faculty of Health, University of Plymouth.

Qualifications

I obtained my 5-years degree in Biochemistry in the University of the Basque Country, Spain, with an average grade of 9.18/10 (2001-2006). Then, I moved to the Autonomous University of Madrid and joined Prof. Marta Izquierdo gene therapy laboratory, at the Center for Molecular Biology “Severo Ochoa” (CBMSO). There, I achieved my PhD titled “Human glioblastoma-derived cancer stem cell characterization. Development of pre-clinic models and therapeutic approaches”, awarded Summa Cum Laude (2006-2010). I stayed at CBMSO as Postdoctoral Research Scientist in Prof. José Maria Almendral, and Dra Lourdes Ruíz Desviat and Dra Belén Pérez González labs (2010-2015). Finally, I moved to the Peninsula Medical School, University of Plymouth, where I joined as Research Fellow in Cancer Stem Cell Neurobiology at Claudia Barros lab (2015-present).


Professional membership

Member of the British Society for Developmental Biology

Research interests

My major scientific interest is biomedicine, from basic to translational, being particularly interested in the intersection of neural development with neoplastic transformation.

My PhD focused on neuro-oncology, specifically in glioblastoma stem cells (GSCs). I derived and characterized different GSCs lines from human GBMs, and I used them to develop human GBM rodent models that closely mirrored the original phenotype. Moreover, I challenged the models with different anti-tumoral gene therapy strategies in vitro and in vivo.

During my first postdoctoral steps I studied the use of parvovirus as selective oncolytic virotherapy agent on these GBM models. Furthermore, I collaborated on the modelling of metabolic disorders generating and characterising iPS cells reprogrammed from patient-derived fibroblasts.

Since I joined Claudia Barros laboratory at Peninsula Medical School (University of Plymouth), I have continued studying neural stem cells (NSCs) during health and disease. We benefit of the exceptional advantages of the post-embryonic Drosophila brain for our unique approach combining live single-cell transcriptomics and functional genetics. Subsequently, we translate the findings into human biology using human brain tissues, NSC and GSC.

In this laboratory, I have been involved in projects aiming to decipher key factors for NSC reactivation and to understand the spatio-temporal regulation of the molecular identity of different types of NSC. Currently, I am focused on the early events that drive the transformation of a NSC into a brain tumour initiating cell. Our aim is to shed light on brain tumour initiation and development and identify potential therapeutic targets.


Journals

Gil-Ranedo J*, Gonzaga E*, Jaworek KJ, Berger C, Bossing T, Barros CS. STRIPAK Members Orchestrate Hippo and Insulin Receptor Signaling to Promote Neural Stem Cell Reactivation. Cell Reports (2019). (*Co-first authors).

Gil-Ranedo J, Hernando E, Valle N, Riolobos L, Maroto B, Almendral JM. Differential phosphorylation and n-terminal configuration of capsid subunits in parvovirus assembly and viral trafficking. Virology (2018).

Gil-Ranedo J*, Hernando E*, Riolobos L, Domínguez C, Kann M, Almendral JM. The Mammalian Cell Cycle Regulates Parvovirus Nuclear Capsid Assembly. PLoS Pathogens (2015). (*Co-first authors).

Mendiburu-Eliçabe M, Gil-Ranedo J. Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts. Curr Cancer Drug Targets (2015).

Mendiburu-Eliçabe M, Gil-Ranedo J*, Izquierdo M. Efficacy of rapamycin against glioblastoma cancer stem cells. Clin Transl Oncol (2014). (*Co-first authors).

Gil-Ranedo J, Mendiburu-Eliçabe M, García-Villanueva M, Medina D, del Álamo M, Izquierdo M. An off-target nucleostemin RNAi inhibits growth in human glioblastoma-derived cancer stem cells. PLoS One (2011).